It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
SARS-CoV-2 infection-induced aggravation of host innate immune response not only causes tissue damage and multiorgan failure in COVID-19 patients but also induces host genome damage and activates DNA damage response pathways. To test whether the compromised DNA repair capacity of individuals modulates the severity of COVID-19 infection, we analyze DNA repair gene expression in publicly available patient datasets and observe a lower level of the DNA glycosylase NEIL2 in the lungs of severely infected COVID-19 patients. This observation of lower NEIL2 levels is further validated in infected patients, hamsters and ACE2 receptor-expressing human A549 (A549-ACE2) cells. Furthermore, delivery of recombinant NEIL2 in A549-ACE2 cells shows decreased expression of proinflammatory genes and viral E-gene, as well as lowers the yield of viral progeny compared to mock-treated cells. Mechanistically, NEIL2 cooperatively binds to the 5’-UTR of SARS-CoV-2 genomic RNA to block viral protein synthesis. Collectively, these data strongly suggest that the maintenance of basal NEIL2 levels is critical for the protective response of hosts to viral infection and disease.
NEIL2, a mammalian DNA repair enzyme, has been reported to suppress infection induced inflammation. Here, the authors characterize its role in modulating the severity of SARS-CoV-2 infection.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 University of Texas Medical Branch, Department of Internal Medicine, Galveston, USA (GRID:grid.176731.5) (ISNI:0000 0001 1547 9964)
2 University of California, San Diego, Department of Chemistry and Biochemistry, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); SRM University-AP, Department of Biological Sciences, School of Engineering and Sciences, Guntur District, India (GRID:grid.473746.5)
3 University of Texas Medical Branch, Department of Microbiology and Immunology, Galveston, USA (GRID:grid.176731.5) (ISNI:0000 0001 1547 9964)
4 Immunology Allergy and Rheumatology, Baylor College of Medicine, Department of Medicine, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X)
5 University of California, Department of Pathology, San Diego, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); University of Massachusetts-Lowell, Department of Biomedical and Nutritional Science, Lowell, USA (GRID:grid.225262.3) (ISNI:0000 0000 9620 1122)
6 UC San Diego Medical Center, Department of Internal Medicine, Division of Cardiology, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
7 University of California San Diego, Department of Cellular and Molecular Medicine, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
8 Life Sciences Division, Lawrence Berkeley National Laboratory, Department of Cancer and DNA Damage Responses, Berkeley, USA (GRID:grid.184769.5) (ISNI:0000 0001 2231 4551)
9 University of Texas Medical Branch, Department of Neurology, Galveston, USA (GRID:grid.176731.5) (ISNI:0000 0001 1547 9964)
10 University of California, Department of Medicine, San Diego, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
11 University of California San Diego, Department of Pediatrics, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); University of California San Diego, Department of Computer Science and Engineering, Jacob’s School of Engineering, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
12 University of California, San Diego, Department of Chemistry and Biochemistry, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
13 University of California San Diego, Department of Cellular and Molecular Medicine, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); University of California, Department of Medicine, San Diego, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)